Innovent Biologics, Inc. · HKEX:1801
Innovent Biologics — 40th Annual J.P. Morgan Healthcare Conference (January 2022)
26 slides from Innovent Biologics's conference presentation, Jan 11, 2022
Slide 1: Transforming to Global Innovation
J.P. Morgan Healthcare Conference Transforming to Global Innovation Dr. Michael Yu, Founder, Chairman and CEO January 11, 2022 To develop and commercialize high quality biopharmaceuticals that are affordable to ordinary people
Slide 2: Disclaimer
Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of Innovent Biologics (“Innovent” “we,” “us” or “our”), our bu
Slide 3: Innovent's First 10 Years Growth: A Solid Track Record
Innovent’s First 10 Years Growth: A Solid Track Record 6 20 60000L 23 6000 commercial clinical capacity in global experienced products assets operation partnerships talents ● 2021 1H total product ● 5 assets in NDA or ● 60K liter capacity in ● Strategic collaboration ● 3,000 sales & revenue over RMB
Slide 4: 2021: Another Successful Year
2021: Another Successful Year COMMERCIAL ✓ Achieved robust PORTFOLIO TYVYT® BYVASDA® SULINNO® HALPRYZA® Pemazyre® Olverembatinib® revenue growth (Taiwan market) 2021 new launch • REGULATORY APPROVALS • REGULATORY FILINGS TYVYT® (PD-1): 1L nsqNSCLC, 1L sqNSCLC, 1L HCC TYVYT® (PD-1) 1L nsqNSCLC (US BL
Slide 5: Sintilimab since Launch: Maintaining Strong Growth Momentum and Leading Market Share in China
Sintilimab since Launch: Maintaining Strong Growth Momentum and Leading Market Share in China Revenue Growth Continue Leadership and Topline Growth ● The only PD-1 with three first-line indications included in NRDL since Jan. 2022 ( 1L nsqNSCLC, ￥2,289 mn 1L sqNSCLC, 1L HCC) ￥2,200+mn ● Extensive ne
Slide 6: Sintilimab in 2021: Only PD-1 Inhibitor with Positive Phase 3 Data in First Line
Sintilimab in 2021: The Only PD-1 Inhibitor with Positive Phase 3 Data in the First Line Treatment of 5 Major Types of Cancer 1L ESCC EGFRm nsqNSCLC 1L sqNSCLC 2021.06 ORIENT-15 met endpoints 2021.11 ORIENT-31 met endpoints 2021.06 sNDA Approval 2021.09 sNDA Accepted 2021.12 sNDA Accepted 1L GC 1L n
Slide 7: Building Solid Foundations and a Robust Pipeline
Building Solid Foundations and a Robust Pipeline Global Innovation Therapeutic Areas Assets Platform Innovent Academy Immunology Six Approved Global R&D -Solid foundation Discovery: 300+ Immunology Oncology Product Development: 1,200+ Cancer Biology Five at late stage Ophthalmology - Near term growt
Slide 8: Building on Our Oncology Pipeline with Immuno-Oncology Focus
Building on Our Oncology Pipeline with Immuno-Oncology Focus Approved Pivotal Stage PD-1 (TYVYT) Sintilimab CD47 (IBI188) VEGF (BYVASDA) Bevacizumab biosimilar PoC Stage Increasing Novelty of the mAb and bi-Abs CTLA-4 (IBI310) CD20 (HALPRYZA) Rituximab biosimilar LAG3 (IBI110) PI3kδ (IBI376) FGFR (P
Slide 9: Enriching Our Pipeline with New Platform Technologies and New Therapeutic Areas
Enriching Our Pipeline with New Platform Technologies and New Therapeutic Areas Solid foundation with de-risked, abundant 80+ Research Programs Well Planned Portfolio Pipeline for Accelerated Growth portfolio for early success Global FIC/BIC Blockbuster Well planned global portfolio for accelerated
Slide 10: Sintilimab in 2022 forward: Keep Expanding Boundaries Globally with Eli Lilly
Sintilimab in 2022 forward: Keep Expanding Boundaries of Sintilimab’s Potential Globally in Collaboration with Eli Lilly Ph1b Pivotal NDA/ Sintilimab (IBI308) Pre-clinical Ph1 /Ph2 Ph2/Ph3 Approved China Market Six major types: 1L nsqNSCLC, 1L sqNSCLC, 1L HCC, 1L ESCC, 1L GC, EGFRm nsqNSCLC Global M
Slide 11: Assets with Positive PoC Results
Assets with Positive PoC Results 1. IBI-112: IL23, p19 We achieved 2. IBI-188: CD47 positive PoC 3. IBI-302: VEGF/Complement readouts for 6 4. IBI-310: CTLA-4 promising assets in 5. IBI-326: BCMA CART the past 6 months 6. IBI-362: GLP-1/GCGR Confidential Copyright© 2022 Innovent 11
Slide 12: IBI-188: A Potentially Best-in-class, Highly-potent CD47 mAb
IBI-188: A Potentially Best-in-class, Highly-potent CD47 mAb A highly potent CD47 mAb Clinical PoC validated; Phase 3 in 1H22 ● Induce tumor clearance by macrophage, mechanistically synergize ● High binding affinity to tumor cell with best-in-class potential with other tumor clearance therapy(chemo,
Slide 13: CD47 mAb (IBI-188): Preliminary Results of Phase 1b PoC Study for MDS
CD47 mAb (IBI-188): Preliminary Results of Phase 1b PoC Study for MDS Phase 1b Study: 1L MDS Optimal Dose Regimen 1L MDS Azacitidine + IBI188 Azacitidine 75mg/m2 D1-D7 every cycle, 28 days one cycle Death Continue Study Identifier: NCT04485065 Weeks • Dose regimen has been optimized in the Phase 1b
Slide 14: IBI-326: A Second Generation Fully Human BCMA Targeting CAR-T Cells
IBI-326: A Second Generation Fully Human BCMA Targeting CAR-T Cells, Potentially First Approved Product in China A SECOND GENERATION FULLY HUMAN BCMA TARGETING CAR-T An innovative cell therapy co-developed by Innovent and IASO SP VL L VH CD8a Hinge & TM 4-1BB CD3 Fully Human scFvs NMPA’s Breakthro
Slide 15: IBI-326: Remarkable Efficacy and Persistency Data in Pivotal Study
IBI-326: Remarkable Efficacy and Persistency Data in Pivotal Study A Phase 1/2 Study of A Novel Fully Human BCMA-targeting CAR-T Cells in Key data Patients With Relapsed / Refractory Multiple Myeloma IBI326 Abecma Development 4LMM pivotal Ph2, 4L MM approved by ◼ 79 enrolled subjects received RP2D:
Slide 16: IBI-302: A Global First-in-class VEGF/Complement Molecule
IBI-302: A Global First-in-class VEGF/Complement Molecule, Visual Acuity Improvement with Edema Reduction Phase 1b Proof OF Concept Study in wet-AMD PoC Findings Phase 1b Result: ● The efficacy in BCVA (Best corrected visual acuity) and macular Change of BCVA from Baseline edema were observed in all
Slide 17: IBI-362: A GLP-1/GCGR, Potentially the Best Molecule to Treat Obesity
IBI-362: A GLP-1/GCGR, Potentially the Best Molecule to Treat Obesity 12 Week Proof Of Concept Study In Obesity PoC Findings ● IBI362 (Low-moderate dose) is comparable to Semaglutide 2.4mg on weight loss in patients with obesity; while in Ph1b study, high Phase 1b Result: dose expended cohort achiev
Slide 18: IBI-362: A GLP-1/GCGR, Potentially Best Molecule to Treat Diabetes
IBI-362: A GLP-1/GCGR, Potentially Best Molecule to Treat Diabetes 12 Week 12 Week Proof Proof Of Concept Of Concept Study In Diabetes In Diabetes PoC Findings Phase 1b Result: HbA1c reduction from baseline to week 12 ● HbA1c mean changes from baseline to week 12 were −1.46%, (after excluded patient
Slide 19: Anticipated Catalysts in 2022
Anticipated Catalysts in 2022 1 2 3 4 5 6 Regulatory Regulatory New Phase 3 Key PoC PoC/Phase 2 First-in-human Actions Filings /Pivotal studies readouts data release assets • Sintilimab(PD-1): 1L GC • IBI376 (PI3Kδ): FL • IBI188 (CD-47): 1H2022, • IBI110 (LAG3): 1H2022 • IBI188 (CD-47): 1H2022, • IB
Slide 20: We have a clear strategy to become a world class biopharmaceutical company
We have a clear strategy to become a world class biopharmaceutical company ▪ Expand business to ▪ Internally focus on 7 ▪ Continue expansion of ▪ Leverage BD to include more global major research commercial portfolio empower internal R&D development for taskforces to deliver and performance and fuel
Slide 21: Continue Expansion of Commercial Portfolio and Performance
Continue Expansion of Commercial Portfolio and Performance Sales Revenue of Commercial Portfolio (RMB, Million) 1,855 1,447 Olverembatinib PI3Kδ PCSK9 (BCR-ABL) (IBI376) (IBI306) Pemazyre® 921 (Pemigatinib)2 ROS1/NTRK BCMA CAR-T SULINNO® (IBI344) (IBI326) 684 (adalimumab) BYVASDA® CTLA-4 Early-stage
Slide 22: Expanding Business to Include More Global Development
Expanding Business to Include More Global Development LAG-3 CD47 TIGIT VEGF-based Bispecific IBI302 (VEGF/C3) We have 4 clusters of molecules with IBI110 (LAG-3) IBI188 (CD47) IBI939 (TIGIT) IBI324 (VEGF/ANG-2) global and blockbuster potential for PoC IBI323 (PD-L1/LAG-3) IBI322 (PD-L1/CD47) IBI321
Slide 23: Internally Focus on 7 Major Research Taskforces to Deliver Global Potential Drugs
Internally Focus on 7 Major Research Taskforces to Deliver Global Potential Drugs With the goal to discover, develop and commercialize potential global blockbuster drugs by 2030, we have 80 research programs at pre-clinical stage supported by state-of-the-art protein and antibody engineering technol
Slide 24: Innovent is Your Preferred Partner in China
Innovent is Your Preferred Partner in China “from product development to commercial launch” Building Platforms Unlocking Value of Regional Pioneering MNC for the Future Best-in-class Partnering In-house R&D Partnerships Biotech Assets Establishing a world-class “Lilly/Innovent” most comprehensive Pa
Slide 25: Key Takeaways
Key Takeaways We have a proven track record with sustained strong performance D We are building solid foundations and an expanding robust pipeline We have a clear strategy to take us to the next level: a world-class biopharmaceutical company Confidential Copyright© 2022 Innovent 25
Slide 26: Long-Term Vision
Long-Term Vision Developing core competiveness 2030 based on strategic vision, global 2025 talent and strong execution • More commercialized • Expanded products, including 2021 commercialized first-in-class products in China blockbusters launched globally • Multiple products • 6 commercialized appro
Innovent Biologics — 40th Annual J.P. Morgan Healthcare Conference (January 2022) on 6ix